Clal Insurance Enterprises Holdings Ltd Has $621.34 Million Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Clal Insurance Enterprises Holdings Ltd increased its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 6.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 34,543,812 shares of the company's stock after purchasing an additional 2,204,623 shares during the period. Teva Pharmaceutical Industries makes up approximately 5.5% of Clal Insurance Enterprises Holdings Ltd's investment portfolio, making the stock its 4th largest holding. Clal Insurance Enterprises Holdings Ltd owned about 3.05% of Teva Pharmaceutical Industries worth $621,337,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in TEVA. Maple Rock Capital Partners Inc. increased its position in shares of Teva Pharmaceutical Industries by 68.3% during the first quarter. Maple Rock Capital Partners Inc. now owns 4,363,401 shares of the company's stock worth $61,568,000 after acquiring an additional 1,770,000 shares in the last quarter. National Pension Service boosted its position in shares of Teva Pharmaceutical Industries by 107.3% during the third quarter. National Pension Service now owns 3,170,640 shares of the company's stock worth $57,135,000 after buying an additional 1,640,940 shares during the period. Iron Triangle Partners LP grew its holdings in shares of Teva Pharmaceutical Industries by 113.1% during the first quarter. Iron Triangle Partners LP now owns 2,769,864 shares of the company's stock worth $39,083,000 after buying an additional 1,469,864 shares in the last quarter. Driehaus Capital Management LLC bought a new stake in Teva Pharmaceutical Industries in the 2nd quarter valued at approximately $23,115,000. Finally, Davidson Kempner Capital Management LP boosted its position in Teva Pharmaceutical Industries by 152.5% during the 2nd quarter. Davidson Kempner Capital Management LP now owns 1,765,485 shares of the company's stock worth $28,689,000 after acquiring an additional 1,066,150 shares during the last quarter. Institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Price Performance

Shares of Teva Pharmaceutical Industries stock traded up $0.04 on Friday, reaching $17.12. 7,441,607 shares of the stock were exchanged, compared to its average volume of 7,721,805. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89. The firm has a market cap of $19.40 billion, a PE ratio of -20.14, a P/E/G ratio of 1.33 and a beta of 0.87. Teva Pharmaceutical Industries Limited has a one year low of $9.35 and a one year high of $19.31. The firm's 50 day moving average is $17.67 and its 200-day moving average is $17.32.

Insider Activity

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the sale, the executive vice president now owns 44,104 shares in the company, valued at $744,034.48. This represents a 30.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.55% of the company's stock.

Analyst Upgrades and Downgrades

TEVA has been the topic of a number of research reports. Barclays boosted their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 23rd. UBS Group lifted their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a "buy" rating in a research report on Tuesday, September 3rd. JPMorgan Chase & Co. increased their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a "neutral" rating in a research report on Monday, October 21st. Finally, StockNews.com raised Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research report on Thursday, October 17th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $19.67.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.